NCL Method STE-3
Mycoplasma is a form of bacteria that lacks a nucleus and a cell wall, and are thus unaffected by many antibiotics. Nanoparticles submitted to the NCL may be subjected to testing for mycoplasma when deemed necessary. The types of nanoparticle...
Listed in Datasets | publication by group NCL Protocols
Version 2.0 - published on 27 Jan 2020 doi:10.17917/QCFR-6F07 - cite this Last public release: 3.0
Licensed under these terms
Description
The NCL does not perform mycoplasma testing in our laboratory. Rather, this test is
outsourced to another department within the Frederick National Laboratory for Cancer Research,
the Protein Expression Laboratory (PEL), within the Cancer Research Technology Program.
Briefly, the NCL will culture nanoparticles with cells for the initial 24 hours, then
passage these cells twenty five (25) times. The supernatants from the final culture will then be
transported to PEL for mycoplasma testing via the VenorGem Mycoplasma PCR-based
Detection Kit from Minerva Biolab
Content List
NCL_Method_STE-3_Sep2015.pdf(PDF | 114 KB)
Cite this work
Researchers should cite this work as follows:
- Crist, R. (2020). NCL Method STE-3. (Version 2.0). NCI Hub. doi:10.17917/QCFR-6F07
NCL Protocols
This publication belongs to the NCL Protocols group.
When watching a publication, you will be notified when a new version is released.